Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT
The obesity drugs made by compounding pharmacies are given by injection, so attention to sterile production is critical to avoid contamination that could cause infections
It's available for $149-$349 with cash-pay, or there are copay cards for those with commercial insurance to keep patient costs to $25/month
Tirzepatide SURMOUNT-1 (2022) and SURPASS-2 (2021) SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 non-diabetic adults with BMI 30, 72 weeks of tirzepatide 15 mg/week: Weight loss: 20.9% (vs 3.1% placebo) 91% of participants 5% loss, 56.7% 20% SURPASS-2 (Fras et al., NEJM 2021): 1,879 T2D patients head-to-head vs semaglutide 1 mg: HbA1c: 2.30% (tirzepatide 15 mg) vs 1.86% (semaglutide) Weight loss: 11.2 kg vs 5.7 kg Tirzepatide statistically outperforms semaglutide on both HbA1c and weight in a head-to-head trial a rare outcome in incretin pharmacology
Phase 3 trials (the TRIUMPH programme) are ongoing
106 stergaardLFrandsenCSMadsbadS
